D Schermuly-Haupt [30], the instrument is more of a tool for improving the therapist’s ability to detect negative Anlotinib price effects than a scale with distinguishable psychometric properties, although it has been used in at least one clinical trial [42].PLOS ONE | DOI:10.1371/journal.pone.0157503 June 22,3 /The Negative Effects QuestionnaireAs for other instruments, the Inventory for …
Continue reading “D Schermuly-Haupt [30], the instrument is more of a tool for improving”